Related Experiment Video

Updated: Apr 29, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

2.1K

[Endothelial dysfunction gene polymorphisms and the rate of liver fibrosis in chronic hepatitis C]

O V Taratina, T N Krasnova, L M Samokhodskaia

    Terapevticheskii Arkhiv
    |May 29, 2014
    PubMed

    Insights

    The TT genotype of the CYBA gene is linked to faster fibrosis progression in chronic hepatitis C (CHC) patients. This finding suggests it may be a marker for a poorer CHC disease course.

    Area of Science:

    • Genetics
    • Hepatology
    • Molecular Biology

    Background:

    • Chronic hepatitis C (CHC) is a significant cause of liver fibrosis and cirrhosis.
    • Genetic factors may influence the rate of fibrosis progression in CHC.
    • Polymorphisms in genes like CYBA, NOS3, and MTHFR are potential determinants of disease severity.

    Purpose of the Study:

    • To investigate the association between specific gene polymorphisms (CYBA, NOS3, MTHFR) and the rate of liver fibrosis progression in CHC patients.
    • To identify genetic markers that could predict rapid fibrosis advancement in CHC.
    • To evaluate the role of CYBA C242T, NOS3, and MTHFR gene variants in CHC pathogenesis.

    Main Methods:

    • A cohort of 109 CHC patients with documented fibrosis stages were analyzed.
    • Patients were categorized into rapid (≥0.130 units/year) and slow (<0.130 units/year) fibrosis progression groups.
    • Gene polymorphisms were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, with 299 healthy donors as a control group.

    Main Results:

    • The TT genotype of the CYBA gene (C242T locus) was significantly more prevalent in patients with rapidly progressive fibrosis compared to those with slow progression (OR 9.09, p=0.0161).
    • No significant differences in the distribution of NOS3 and MTHFR gene alleles or genotypes were observed between the rapid and slow fibrosis progression groups.
    • The CYBA TT genotype emerged as a potential indicator of accelerated fibrosis in CHC.

    Conclusions:

    • The TT genotype of the CYBA gene at the C242T locus is associated with a profibrogenic effect in CHC.
    • This specific CYBA genotype may serve as a marker for predicting a more severe or aggressive course of chronic hepatitis C.
    • Further research into CYBA's role could inform personalized treatment strategies for CHC patients.
    Abstract

    More Related Videos

    In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion12:35

    In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion

    Published on: November 10, 2011

    20.3K
    A Standardized Method for the Analysis of Liver Sinusoidal Endothelial Cells and Their Fenestrations by Scanning Electron Microscopy08:38

    A Standardized Method for the Analysis of Liver Sinusoidal Endothelial Cells and Their Fenestrations by Scanning Electron Microscopy

    Published on: April 30, 2015

    14.4K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    382
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
    41
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    271
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    157
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    191
    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

    Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
    337